Itratuf 200 Capsule contains Itraconazole 200 mg, a broad-spectrum triazole antifungal agent used for the treatment of various fungal infections. Itraconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. It is indicated for the management of systemic and superficial mycoses, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. Itratuf 200 Capsule is administered orally and is well-absorbed, with bioavailability enhanced when taken with food. The drug undergoes hepatic metabolism primarily via the cytochrome P450 system, necessitating caution with concomitant medications due to potential drug interactions. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain, as well as headache and rash. Itraconazole should be used cautiously in patients with hepatic impairment, congestive heart failure, or those receiving medications that prolong the QT interval. Regular monitoring of liver function tests and clinical response is recommended during prolonged therapy. Itratuf 200 Capsule provides an effective antifungal option for clinicians managing resistant or invasive fungal infections, ensuring improved patient outcomes when used appropriately.